

CONGRESSO NAZIONALE  
**78**  
FIMMG-METIS 2021

# MEDICINA GENERALE CONVENZIONATA, DIRITTO DELL'INDIVIDUO.

**RESIDENZIALE  
E VIDEOCONFERENZA**  
4 OTTOBRE 2021  
9 OTTOBRE 2021

**FAD ASINCRONE**  
12 OTTOBRE 2021  
15 NOVEMBRE 2021



SCelta FIDUCIARIA  
PROSSIMITÀ  
DOMICILIARITÀ

**FIMMG**<sup>®</sup>  
Federazione Italiana Medici di Famiglia

**Metis**<sup>®</sup>  
SOCIETÀ SCIENTIFICA DEI MEDICI  
DI MEDICINA GENERALE





# Innovazione nella prevenzione dell'Herpes zoster: nuovi strumenti per il medico di medicina generale

Evoluzione della profilassi vaccinale anti Herpes Zoster e sue indicazioni

ROBERTO IERACI

## Vaccino Zoster vivo attenuato - ceppo Oka

- autorizzato in Europa (EMA) nel 2006 e in Italia (AIFA) nel 2010
- in commercio in Italia da marzo 2014
- una sola dose
- negli Stati Uniti non più disponibile per l'uso dal 18 novembre 2020





Evaluation of the effect of chickenpox vaccination on shingles epidemiology using agent-based modeling

Ellen Rafferty<sup>1</sup>, Wade McDonald<sup>2</sup>, Weicheng Qian<sup>2</sup>, Nathaniel D. Osgood<sup>2</sup> and Alexander Doroshenko<sup>3</sup>



## RZV approccio originale ed innovativo: antigene ricombinante + nuovo adiuvante







- **RZV indicato per la prevenzione dell'Herpes Zoster (HZ) e della nevralgia post-erpetica (PHN)**
- **adulti di età =>50 anni**
- **adulti di età => 18 anni ad aumentato rischio di HZ**

- ✓ **somministrato per via IM**
- ✓ **schedula a 2 dosi**

- **ben tollerato**
- **reazioni maggiormente osservate**
  - **dolore nel sito di iniezione**
  - **mialgia**
  - **affaticamento**
  - **cefalea**





- non fornisce indicazioni preferenziali fra i due vaccini



## Board del Calendario per la Vita




OGGETTO: Aggiornamento sulla vaccinazione contro Herpes zoster



- utilizzo del ricombinante adiuvato a 2 ds in grado di prevenire un maggior numero di casi di HZ e Nevralgia Post Erpetica (NPE) in tutte le fasce di età rispetto ad 1 ds di vaccino vivo attenuato
- induce un'efficacia sul campo più duratura nel tempo



## Vaccino Zoster Ricombinante (RZV): schedula



**RZV si può co-somministrare con gli altri vaccini previsti per l'adulto:**

- ✓ anti-influenzale quadrivalente (IIIV) (non adiuvato)
- ✓ anti-difterite-tetano-pertosse (Tdap)
- ✓ anti-pneumococcico 23-valente (PPS23v)







Menu de la publication

← Typh-O : vaccin oral contre la typhoïde

Zona-VA : vaccin vivant atténué contre le zona

## Vaccins

### Zona-SU : vaccin sous-unitaire contre le zona

Composition	Présentation	Indications	Contre-indications	Précautions	Interactions
Recherche d'anticorps	Manifestations cliniques après la vaccination	Administration	Réponse au vaccin		

#### Composition

Un vaccin inactivé contre le **zona** est distribué au Canada : Shingrix (GSK).

Il s'agit d'un vaccin adjuvanté qui inclut la glycoprotéine E du virus varicelle-zona. Cette glycoprotéine est produite par la technologie de l'ADN recombinant dans des cellules ovariennes de hamster.

Chaque dose de Shingrix contient :

- 50 µg de glycoprotéine E du virus varicelle-zona;
- l'adjuvant AS01B, comprenant 50 µg de 3-O-désacyl-4'-monophosphoryl lipide A et 50 µg de Fraction 21 de *Quilfolia saponaria Molina*;
- les excipients de la poudre (vaccin lyophilisé) : phosphate dipotassique, Polysorbate 80, dihydrogénophosphate de sodium dihydraté, saccharose;
- les excipients de la suspension liquide (adjuvant) : cholestérol, dioléoyl phosphatidylcholine, phosphate disodique anhydre, dihydrogénophosphate de potassium, chlorure de sodium, eau.

#### Présentation

- Shingrix :
  - Fliale unidose de vaccin lyophilisé et fliale d'adjuvant, utilisé comme diluant.

Le vaccin reconstitué a l'aspect d'une solution opalescente, incolore ou légèrement brunâtre.

#### Indications

Le CIQ recommande l'utilisation du vaccin Zona-SU de préférence à celle du vaccin Zona-VA.

12 Vacciner les personnes immunodéprimées âgées de 18 ans et plus.

## HZ-su

-molto efficace nel prevenire

- malattia
- gravi complicanze

➤ vaccino di elezione per una delle categorie di cronici > 18: gli immunodepressi



Bekanntmachungen – Amtliche Mitteilungen

Bundesgesundheitsblatt 2019 - 62:352-376  
<https://doi.org/10.1007/s00133-019-02882-5>  
 © Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2019

**A. Siedler<sup>1</sup> · J. Koch<sup>1</sup> · E. Garbe<sup>2</sup> · H. Hengel<sup>3,9</sup> · R. von Kries<sup>4</sup> · T. Ledig<sup>5</sup> · T. Mertens<sup>6</sup> · F. Zepp<sup>7</sup> · K. Überall<sup>8</sup>**

<sup>1</sup>Immunization Unit, Robert Koch Institute, Berlin, Germany  
<sup>2</sup>Bremen Institute for Prevention Research and Social Medicine, University of Bremen, Bremen, Germany  
<sup>3</sup>Institute of Virology, Medical Center – University of Freiburg, Faculty of Medicine, Freiburg, Germany  
<sup>4</sup>Institute of Social Paediatrics and Adolescent Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany  
<sup>5</sup>General Practice, Ditzingen, Germany  
<sup>6</sup>Institute of Virology, Ulm University Medical Center, Ulm, Germany  
<sup>7</sup>Department of Pediatrics and Adolescent Medicine, University Medicine Mainz, Mainz, Germany  
<sup>8</sup>Institute of Clinical and Molecular Virology, University of Erlangen-Nürnberg, Erlangen, Germany  
<sup>9</sup>German Consulting Laboratory for HIV and VZV, Medical Center – University of Freiburg, Freiburg, Germany

### Background paper to the decision to recommend the vaccination with the inactivated herpes zoster subunit vaccine

#### Statement of the German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute

of herpes zoster (HZ) and postherpetic neuralgia (PHN) for all people age 60 years and over (standard vaccination). This recommendation takes into account the good efficacy of the vaccine, the anticipated period of protection it provides and the increased risk of severe HZ disease and post-zoster pain in individuals age 60 years and over. Models of the epidemiological effects of vaccination show that administering the HZ/su vaccine at age 60 years has the greatest effect in preventing all HZ cases, and administering the vaccine at age 70 years showed the greatest effect in preventing PHN, in a vaccinated cohort. According to the results of a health economics model, the lowest cost per quality-adjusted life year (QALY) would be achieved with vaccination at age 65 years. The number of people who need to be vaccinated (number needed to vaccinate, NN<sub>V</sub>) to prevent one case of HZ is the same for both vaccination ages (60 and 65 years). In light of the fact that preventing HZ is the key prerequisite to preventing complications and late sequelae such as PHN, 60 years of age is considered the most favorable age for vaccination, to prevent both HZ and its complications. The STIKO also recommends vaccination against HZ and PHN with the HZ/su inactivated vaccine for all people from the age of 50 years who have an elevated risk of HZ and PHN owing to increased health risks as a consequence of an underlying disease or immunosuppression (indication-based vaccination). This group includes e.g. people with congenital or acquired immunodeficiency or immunosuppression, HIV infection, rheumatoid arthritis, systemic lupus erythematosus, chronic inflammatory bowel disease, chronic obstructive pulmonary disease (COPD) or bronchial asthma, chronic renal disease, diabetes mellitus. The efficacy and safety of the vaccine for patients with impaired immune systems have been demonstrated in numerous studies. Stratified data analyses on the efficacy of the vaccine have shown no difference in

**Electronic supplementary material**  
 The online version of this article (<https://doi.org/10.1007/s00133-019-02882-5>) contains supplementary material, which is available to authorized users.

**Summary**  
 The STIKO recommends vaccination with the adjuvanted herpes zoster subunit (HZ/su) inactivated vaccine for the preven-

352 | Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 3 · 2019



Vaccine 39 (2021) 5240–5250



Conference report

A global agenda for older adult immunization in the COVID-19 era:  
A roadmap for action

Lois A. Privor-Dumm<sup>a,\*</sup>, Gregory A. Poland<sup>b</sup>, Jane Barratt<sup>c</sup>, David N. Durrheim<sup>d</sup>, Maria Deloria Knoll<sup>e</sup>,  
Prarthana Vasudevan<sup>f</sup>, Mark Jit<sup>g</sup>, Pablo E. Bonvehi<sup>h</sup>, Paolo Bonanni<sup>g</sup>,  
on behalf of the International Council on Adult Immunization<sup>1</sup>

<sup>a</sup>International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

<sup>b</sup>Mayo Vaccine Research Group, Mayo Clinic and Foundation, Rochester, MN, USA

<sup>c</sup>International Federation on Ageing, Toronto, Canada

<sup>d</sup>Public Health Medicine, University of Newcastle, Wallsend, NSW, Australia

<sup>e</sup>Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, England, United Kingdom

<sup>f</sup>EMIC, Buenos Aires, Argentina

<sup>g</sup>Department of Health Sciences, University of Florence, Florence, Italy

<sup>h</sup>Department of Health Sciences, University of Florence, Florence, Italy

- **HZ-su autorizzato nei soggetti ad aumentato rischio di HZ a partire dai 18 anni**
- **vaccino di elezione se la strategia attualmente vigente per gli over 50 estesa agli under 50**
- **operatori sanitari vaccinatori hanno un ruolo fondamentale contro l'esitazione dei vaccini**
- **campagne incentrate sui MMG e informazioni accessibili offerte al pubblico migliorano notevolmente l'accettazione della vaccinazione HZ**

## VACCINAZIONI NELLE MALATTIE REUMATOLOGICHE: SICUREZZA ED EFFICACIA

Guida pratica per il medico di medicina generale e lo specialista reumatologo

Aggiornamento al 5 ottobre 2020

**Esperienza Lazio: predisposizione PO di vaccinazione per HZ promosso e gestito centralmente dalla Regione come per influenza e pneumococco**

per :

- **rilancio dell'intervento HZ**
- **coinvolgimento attivo dei MMG**
- **definizione aspetti logistico-organizzativi**



## Piano Nazionale Prevenzione Vaccinale

PNPV 2017-2019

❖ Coorte dei soggetti di 65 anni di età con chiamata attiva a partire dall'anno 2018

❖ Soggetti con fattori di rischio a partire dai 50 anni di età

✓ Diabetici

✓ BPCO

✓ Patologie Cardiovascolari

✓ Soggetti destinati a terapie immunosoppressive



la vaccinazione contro HZ nel Lazio come nelle altre Regioni non è mai decollata

raggiungimento del 50% di copertura nei 65enni

2018	2019	2020
20%	35%	50%

RZV più maneggevole

- destinato ad una platea più ampia di soggetti erogatori i MMG

offerta vaccinale equa accessibile per la presenza capillare dei 64.00 studi di MMG valorizzata da un approccio «personalizzato realizzando in tal modo una “prevenzione di precisione” adeguata ai bisogni del singolo paziente



## CDC recommends new shingles vaccine (Shingrix) for adults 50 and older

patients:  
**50+**  
years old

doses:  
2-6 months  
apart

administer:  
intra-  
muscular  
in the  
deltoid

storage:  
36°-46°  
refrigerate

- RZV raccomandato per le persone di età >50anni
- HZ/su preferito rispetto a ZVL >50anni indipendentemente dalla storia di HZ o dalla precedente vaccinazione con ZVL
- ACIP sconsiglia la somministrazione di HZ/su a meno di 2 mesi dopo aver ricevuto ZVL
- ACIP raccomanda HZ-su preferito rispetto a ZVL > 60anni



Protecting and improving the nation's health

**IDSA**  
Infectious Diseases Society of America



**VACCINE**  
RECOMMENDED FOR  
**AGES 50+**  
MORE EFFECTIVE THAN  
OLD VACCINE

SOURCE: CDC

Morbidity and Mortality Weekly Report

### Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines

Kathleen L. Dooling, MD<sup>1</sup>; Angela Guo, MPH<sup>1</sup>; Manisha Patel, MD<sup>1</sup>; Grace M. Lee, MD<sup>1</sup>; Kelly Moore, MD<sup>1</sup>; Edward A. Belongia, MD<sup>1</sup>; Rafael Harpaz, MD<sup>1</sup>



#### Introduction

On October 20, 2017, Zoster Vaccine Recombinant, Adjuvanted (Shingrix; GlaxoSmithKline, [GSK] Research Triangle Park, North Carolina), a 2-dose, subunit vaccine containing recombinant glycoprotein E in combination with a novel adjuvant (AS01a), was approved by the Food and Drug Administration for the prevention of herpes zoster in adults aged  $\geq 50$  years. The vaccine consists of 2 doses (0.5 mL each), administered intramuscularly, 2–6 months apart (1). On October 25, 2017, the Advisory Committee on Immunization Practices (ACIP) recommended the recombinant zoster vaccine (RZV) for use in immunocompetent adults aged  $\geq 50$  years.

Herpes zoster is a localized, usually painful, cutaneous eruption resulting from reactivation of latent varicella zoster virus (VZV). Herpes zoster is common; approximately one million cases occur each year in the United States (2). The incidence increases with age, from five cases per 1,000 population in adults aged 50–59 years to 11 cases per 1,000 population in persons aged  $\geq 80$  years (2). Postherpetic neuralgia, commonly defined as persistent pain for at least 90 days following the resolution of the herpes zoster rash, is the most common complication and occurs in 10%–13% of herpes zoster cases in persons aged  $\geq 50$  years (3,4). Among persons with herpes zoster, the risk for developing postherpetic neuralgia also increases with age (3–5).

Zoster Vaccine Live (ZVL) (Zostavax, Merck and Co., Inc., Whitehouse Station, New Jersey), a 1-dose live attenuated strain of VZV, is licensed for the prevention of herpes zoster in immunocompetent adults aged  $\geq 60$  years and is recommended by the ACIP for use in immunocompetent adults aged  $\geq 60$  years (6). Since licensure, vaccine coverage has increased each year, and by 2016, 33% of adults aged  $\geq 60$  years reported receipt of the vaccine (CDC, provisional unpublished data). ACIP considered use of RZV, as well as existing recommendations, to develop vaccination policy which would be safe and reduce disease burden. This report serves as a supplement to the 2008 Prevention of Herpes Zoster Recommendations of ACIP for the use of ZVL in adults aged  $\geq 60$  years and subsequent updates (6–8); it outlines recent ACIP recommendations as well as guidance for use of RZV and ZVL in adults.

#### Methods

From March 2015 to October 2017, the ACIP Herpes Zoster Vaccines Work Group (Work Group; see acknowledgments for members and their affiliations) participated in monthly or bimonthly teleconferences to review herpes zoster epidemiology and the evidence for the efficacy, safety, and programmatic factors of RZV and ZVL. According to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, the Work Group defined critical and important outcomes, conducted a systematic review of the evidence, and subsequently reviewed and discussed findings and evidence quality (<https://www.cdc.gov/vaccines/acip/recs/grade/>) (9).

A cost effectiveness analysis comparing RZV, ZVL, or no vaccine was conducted by CDC from a societal perspective, using an analytic horizon of time of vaccination through the end of life. Model inputs were based on published literature where available and relied on unpublished data and Work Group expert opinion when necessary. It was modeled that ZVL effectiveness against herpes zoster would wane to zero 4–12 years following vaccination, depending on age at vaccination (4,10–13). In the absence of long-term effectiveness data, it was modeled that RZV effectiveness in adults aged 50–69 years or  $\geq 70$  years would wane to zero 19 years following vaccination based on the rate of waning observed during the first 4 years of clinical trials as well as expert opinion (13–15). Economic analyses were also conducted for RZV in cohorts previously vaccinated with ZVL. In keeping with CDC practice (16,17), the purpose of the economic analysis was to model the proposed recommendations; therefore, full adherence to a 2-dose RZV regime was assumed in baseline models. Lower rates of 2-dose adherence were evaluated in sensitivity analyses.

Since 2015, RZV was discussed at five ACIP meetings. In addition to the aforementioned data, several independent health economic studies (18,19), (Merck, unpublished data, 2017), as well as immunogenicity data were presented. Long-term immunogenicity of RZV (20) and immunogenicity and safety of RZV in ZVL recipients (21) were considered, with recognition that there are no standard immunologic correlates of protection for prevention of herpes zoster.

At the October 2017 meeting, three proposed recommendations were presented to the committee, and, after a public

## Vaccination against shingles (Herpes Zoster)

An update for healthcare professionals  
Updated February 2018





Contents lists available at ScienceDirect

Vaccine


journal homepage: [www.elsevier.com/locate/vaccine](http://www.elsevier.com/locate/vaccine)



Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study

Himal Lal<sup>a,1</sup>, Airi Poder<sup>b</sup>, Laura Campora<sup>c</sup>, Brecht Geeraerts<sup>c</sup>, Lidia Oostvogels<sup>c</sup>, Carline Vanden Abeele<sup>c</sup>, Thomas C. Heineman<sup>a,2\*</sup>

<sup>a</sup>CSK, 709 Swedeland Road, King of Prussia, PA 19406, USA  
<sup>b</sup>Kliiniliste Uuringute Keskus, 54 Sobra, 50100 Tartu, Estonia  
<sup>c</sup>CSK, 70 Avenue Fleming, 1300 Wavre, Belgium



The Journal of Infectious Diseases

EDITORIAL COMMENTARY



Clinical Usage of the Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su): Revaccination of Recipients of Live Attenuated Zoster Vaccine and Coadministration With a Seasonal Influenza Vaccine

Michael N. Oxman,<sup>1,2</sup> Ruth Harbecke,<sup>1,2</sup> and David M. Koelle<sup>1,5\*</sup>



Contents lists available at ScienceDirect

Vaccine

journal homepage: [www.elsevier.com/locate/vaccine](http://www.elsevier.com/locate/vaccine)



Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults  $\geq 50$  years of age: A randomized trial

Céline Maréchal<sup>a,4\*</sup>, Himal Lal<sup>b,1</sup>, Airi Poder<sup>c</sup>, Murdo Ferguson<sup>d</sup>, Igwebuie Enweonye<sup>e</sup>, Thomas C Heineman<sup>b,2</sup>, Caroline Hervé<sup>f</sup>, Paul Rheault<sup>g</sup>, Jaak Talli<sup>h</sup>, Dominique Wauters<sup>f</sup>, Lidia Oostvogels<sup>f,3</sup>

The Journal of Infectious Diseases

MAJOR ARTICLE



Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older

Tino F. Schwarz,<sup>1</sup> Naresh Aggarwal,<sup>4</sup> Beate Moeckesch,<sup>2</sup> Isabelle Schenkenberger,<sup>3</sup> Carine Claeys,<sup>5</sup> Martine Douha,<sup>5</sup> Olivier Godeaux,<sup>6</sup> Katrijn Gruppings,<sup>5</sup> Thomas C. Heineman,<sup>2a</sup> Marta Lopez Fauqued,<sup>5</sup> Lidia Oostvogels,<sup>5</sup> Peter Van den Steen,<sup>5</sup> and Himal Lal<sup>1b</sup>

- risposte immunitarie a HZ/su a 0, 6 mesi non inferiori a quelle con un ciclo a 0, 2
- profilo di sicurezza clinicamente accettabile per tutti gli intervalli di dose
- co-somministrazione insieme ad altri vaccini per adulti tra cui Flu IIV4 Pneumo
- non interferenza immunologica tra RZV e PPSV23 nella stessa seduta negli >50 anni
- non problemi di sicurezza



# Risk of Herpes Zoster in Cancer Patients and the Promise of New Vaccines

Kosuke Kawai<sup>1,2</sup> and Barbara P. Yawn<sup>3</sup>

<sup>1</sup>Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, and <sup>2</sup>Harvard Medical School, Boston, Massachusetts; and <sup>3</sup>Department of Family Medicine and Community Health, University of Minnesota, Minneapolis, Minnesota

- immuno-compromessi ad aumentato rischio di sviluppare HZ
- diffusione cutanea e viscerale di VZV comune può portare a complicazioni gravi e pericolose per la vita
- dolore grave può persistere per un lungo periodo: può portare a PHN
- HZ-su non può replicare sicuro anche per gli individui gravemente compromessi
- RZV preferito nei pazienti con cancro raccomandato per  $\geq 50$  anni
- Se vaccinati prima con ZVL, RZV non somministrato prima di 2 mesi

Journal Pre-proof

Herpes Zoster after Recombinant Zoster Vaccine: A First Case Report

Laurie A. Housel, MSN, FNP, Bruce M. McClenathan, MD, FACP, FAAAAI

PII: S2213-2198(19)30651-8

DOI: <https://doi.org/10.1016/j.jaip.2019.07.033>

Reference: JAIP 2389

To appear in: *The Journal of Allergy and Clinical Immunology: In Practice*

Received Date: 11 June 2019



IDSA  
Infectious Diseases Society of America



Original Article

## Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies

Kim A. Papp<sup>1,2</sup>, Boulos Haraoui<sup>3</sup>, Deepali Kumar<sup>4,5</sup>, John K. Marshall<sup>6</sup>, Robert Bissonnette<sup>7</sup>, Alain Bitton<sup>8</sup>, Brian Bressler<sup>9,10</sup>, Melinda Gooderham<sup>2,11</sup>, Vincent Ho<sup>9</sup>, Shahin Jamal<sup>12</sup>, Janet E. Pope<sup>13,14</sup>, A. Hillary Steinhart<sup>5,15</sup>, Donald C. Vinh<sup>8,16</sup>, and John Wade<sup>9,17</sup>

Journal of Cutaneous Medicine and Surgery  
2019, Vol. 23(1) 50–74  
© The Author(s) 2018

Article reuse guidelines:  
sagepub.com/journals-permissions  
DOI: 10.1177/1203475418811335  
journals.sagepub.com/home/jcms

Canadian Dermatology Association  
Association canadienne de dermatologie

CME

- immunosoppressori dis-regolano immunità aumentano il rischio di infezioni
- immunizzazione mitiga significativamente questi rischi

## Uso di biologici immunomodulatori DMARDS e glucocorticoidi

- può provocare attenuazione
- ma non abolire la risposta immunitaria ai vaccini



COCOON STRATEGY

REVIEW ARTICLE

Multiple myeloma gammopathies

### Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

Heinz Ludwig<sup>1</sup> • Mario Boccadoro<sup>2</sup> • Philippe Moreau<sup>3</sup> • Jesus San-Miguel<sup>4</sup> • Michele Cavo<sup>5</sup> • Charlotte Pawlyn<sup>6</sup> • Sonja Zweegman<sup>7</sup> • Thierry Facon<sup>8</sup> • Christoph Driessen<sup>9</sup> • Roman Hajek<sup>10</sup> • Melitios A. Dimopoulos<sup>11</sup> • Francesca Gay<sup>2</sup> • Hervé Avet-Loiseau<sup>12</sup> • Evangelos Terpos<sup>11</sup> • Niklas Zojer<sup>13</sup> • Mohamad Mohty<sup>14</sup> • Maria-Victoria Mateos<sup>15</sup> • Hermann Einsele<sup>16</sup> • Michel Delforge<sup>17</sup> • Jo Caers<sup>18</sup> • Katja Weisel<sup>19</sup> • Graham Jackson<sup>20</sup> • Laurent Garderet<sup>21</sup> • Monika Engelhardt<sup>22</sup> • Niels van de Donk<sup>7</sup> • Xavier Leleu<sup>23</sup> • Hartmut Goldschmidt<sup>24</sup> • Meral Beksac<sup>25</sup> • Inger Nijhof<sup>7</sup> • Niels Abildgaard<sup>26</sup> • Sara Bringhen<sup>2</sup> • Pieter Sonneveld<sup>27</sup>

Received: 8 April 2020 / Revised: 24 July 2020 / Accepted: 5 August 2020 / Published online: 19 August 2020  
© The Author(s) 2020. This article is published with open access


### Vaccinazioni raccomandate nel paziente diabetico adulto

SID, Società Italiana di Diabetologia  
Società Italiana Igiene, Medicina  
Italiana Medici Medicina General  
Cure Primarie

JAMD | www.jamd.it | ISSN 2532-4799 (online) | ISSN 2036-363X (print) vol. 21-3



## somministrazione di RZV in soggetti con anamnesi pregressa di HZ



Vaccine response rates for anti-gE antibody concentrations one month after the second vaccine dose: overall, by age group and by time since previous herpes zoster episode (ATP cohort for immunogenicity).

- RZV provoca una risposta immunitaria forte
- sintomi locali e sistemici sollecitati transitori e per lo più di intensità da lieve a moderata

nessun apparente problema di sicurezza riscontrato post ds 2 di RZV in adulti ≥50 anni con anamnesi pregressa di HZ



## in sintesi

- alta efficacia in tutti i soggetti con più di 50 anni di età (>90%)<sup>1,2</sup>
- elevata efficacia nel tempo con un minimo declino a circa 7 anni dalla vaccinazione <sup>2\*</sup>
- complicazioni da HZ come la NPE fortemente ridotte in tutti i soggetti con più di 50 anni di età<sup>2</sup>
- incidenza complessiva di SAEs decessi e pIMDS è risultata simile nei due gruppi (RZV e placebo)<sup>3</sup>
- sintomi più frequenti dolore al sito di iniezione, mialgia, fatica, mal di testa <sup>1,2</sup>
- maggior parte delle reazioni, locali e sistemiche da lievi a moderate e di breve durata (1–3 giorni)<sup>1,2</sup>

1. Lal H, et al. *N Engl J Med* 2015;372:2087–96;  
2. Cunningham AL, et al. *N Engl J Med* 2016;75:1019–32  
3. Lopez-Fauqued M et al. *Vaccine* 2019; 37(18):2482-2493

### SUMMARY OF THE DISEASE AND THE VACCINE

#### Shingles

- is a common disease that can cause long-lasting, severe pain
- has been known to cause permanent disability
- occurs more frequently in those over 70 who are also more likely to have worse symptoms.

#### The vaccine

- is significantly reducing the number of cases
- will reduce the severity of symptoms in vaccinated people if they develop the disease
- has been used extensively in the USA and Canada
- cannot cause shingles in healthy people



### VACCINAZIONE DELL'ADULTO: LE INNOVAZIONI OLTRE AL COVID-19 E LE RACCOMANDAZIONI SIMIT

Recommendations of the Italian Society for Infectious and Tropical Diseases (SIMIT) for adult vaccinations



RECOMMENDED VACCINES	
RISK POPULATION	RECOMMENDED VACCINES
Adults ≥ 65 years	<b>Influenza</b> - CDC, ECDC, INHS, NHS, NACI, STIKO
	<b>Pneumococcal</b> - CDC, ECDC, INHS, NHS
	<b>Tdap</b> - CDC, ECDC, INHS
	<b>Zoster (recombinant, adjuvanted)</b> - CDC, ECDC, INHS, NACI, STIKO
	<b>COVID-19</b> - CDC, ECDC, INHS, NHS








- i vaccini COVID-19 possono essere somministrati indipendentemente dai tempi di altri vaccini compresi gli anti-influenzali (ciò include somministrazione simultanea del vaccino COVID-19 e altri vaccini nello stesso giorno)

[https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html?CDC\\_AA\\_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2F covid-19%2Finfo-by-product%2Fclinical-considerations.html#Coadministration](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2F covid-19%2Finfo-by-product%2Fclinical-considerations.html#Coadministration)



- non disponibili dati per i vaccini covid somministrati contemporaneamente ad altri vaccini
- immunogenicità e profili eventi avversi generalmente simili quando i vaccini somministrati contemporaneamente o da soli (CDC)
- possibile effettuare somministrazione concomitante (o a qualsiasi distanza di tempo, prima o dopo) di:
  - un vaccino COVID-19 utilizzato in Italia
  - e un altro vaccino del PNPV
- con l'eccezione dei vaccini vivi attenuati per i quali può essere considerata valida una distanza minima di 14 gg prima o dopo la somministrazione del vaccino Covid

Avis n° 2021.0069/AC/SESPEV du 23 septembre 2021 du collège de la Haute Autorité de santé venant compléter l'avis du 23 août 2021 relatif à la définition des populations à cibler par la campagne de rappel vaccinal chez les personnes ayant eu une primovaccination complète contre la Covid-19  
AVIS ET DÉCISIONS DE LA HAS - Mis en ligne le 23 sept. 2021



[https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/39\\_21\\_STIKO\\_Koadministration.pdf?\\_\\_blob=publicationFile](https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/39_21_STIKO_Koadministration.pdf?__blob=publicationFile)

Chapter 14a - COVID-19 - SARS-CoV-2

14a  
COVID-19 - SARS-CoV-2

[https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/1018444/Greenbook\\_chapter\\_14a\\_COVID-19\\_SARS-CoV-2\\_Sept21.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1018444/Greenbook_chapter_14a_COVID-19_SARS-CoV-2_Sept21.pdf)

Beschluss der STIKO zur 11. Aktualisierung der COVID-19-Impfempfehlung

STIKO-Empfehlung zur COVID-19-Impfung

Aktualisierung vom 24. September 2021

3 September 2021

An Advisory Committee Statement (ACS)  
National Advisory Committee on Immunization (NACI)

Recommendations on the use of COVID-19 Vaccines



Protecting and improving the nation's health

COVID-19 vaccination programme

Information for healthcare practitioners

Republished 9 June 2021



Consiglio Superiore di Sanità  
Direzione Generale della Prevenzione Sanitaria



0044591-02/10/2021-DGPRE-DGPRE-P

Intervallo temporale tra la somministrazione dei vaccini anti-SARS-CoV-2/COVID-19 e altri vaccini

Ministero della Salute

DIREZIONE GENERALE DELLA PREVENZIONE SANITARIA

Recommendations for Prevention and Control of Influenza in Children, 2021–2022 Pediatrics September 2021, e2021053744; DOI: <https://doi.org/10.1542/peds.2021-053744>



GRAZIE  
PER L'ATTENZIONE

